Ignite Creation Date:
2024-07-17 @ 11:33 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06470971
Status:
RECRUITING
Last Update Posted:
2024-07-03
First Post:
2024-06-17
Brief Title:
Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer CIRES Trial
Sponsor:
Yuanquan Yang
Organization:
Ohio State University Comprehensive Cancer Center
Organization Data
Organization:
Ohio State University Comprehensive Cancer Center
Class:
OTHER
Study ID:
OSU-23393
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Yuanquan Yang
Lead Sponsor Class:
OTHER
Responsible Party:
Yuanquan Yang
Responsible Party Title:
Principal Investigator
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Ohio State University Comprehensive Cancer Center
Old Name:
None
Old Organization:
None